PAVmed Inc. ($PAVM) reported second-quarter 2026 revenue of $33,000, well below the $48,960 analyst estimate. The company continued to operate at a loss, with gross profit of -$89,000 and operating loss of -$7.0 million.
Net loss attributable to common shareholders came in at -$5.4 million, or -$0.87 per diluted share. That was an improvement from the prior year on a per-share basis, but the company remained deep in the red as expenses continued to outpace revenue.
Cash flow stayed negative in the quarter, with operating cash use of -$2.7 million. PAVmed ended the period with $3.8 million in cash and cash equivalents, while total liabilities climbed to $20.9 million.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
PAVmed Inc. Hedge Fund Activity
We have seen 9 institutional investors add shares of PAVmed Inc. stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC added 24,901 shares (+211.4%) to their portfolio in Q2 2026, for an estimated $147,911
- BLACKROCK, INC. added 14,676 shares (+607.5%) to their portfolio in Q2 2026, for an estimated $87,175
- NORTHERN TRUST CORP removed 3,576 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $36,296
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 2,274 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $23,081
- GSA CAPITAL PARTNERS LLP removed 2,197 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $13,050
- CAPTRUST FINANCIAL ADVISORS removed 2,168 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $22,005
- LPL FINANCIAL LLC removed 1,852 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $18,797
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
